This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
DARA BioSciences, Inc. (NASDAQ: DARA) (the "Company" or "DARA"), a specialty pharmaceutical company focused on oncology and oncology supportive care products, announced today the Company will be presenting at the 15
th Annual BIO CEO & Investor Conference. Hosted by the Biotechnology Industry Organization (BIO), the 15
th Annual BIO CEO & Investor Conference will take place February 11-12 at the Waldorf-Astoria in New York City. David J. Drutz, M.D., CEO and CMO of DARA, will present a corporate overview on Tuesday, February 12
th at 2:00 pm EST.
“DARA has moved quickly to establish a presence in the oncology/oncology support therapeutics space with three FDA-approved products that are highly complementary and, therefore, more efficiently marketed to physicians who treat cancer,” stated Dr. David J. Drutz, DARA's chief executive officer. “DARA has leveraged the efforts of its team of highly experienced regional business directors (RBDs) through the development of relationships with key opinion leaders and healthcare provider organizations, as well as expanding its reach through other programs, including telemarketing. We are pleased to be reaching a broad audience of investors through this prestigious and influential conference.”
About DARA BioSciences, Inc.
DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA has comprehensive commercial coverage across the national oncology market through a series of agreements with a number of specialty pharmacy providers, leading group purchasing organizations (GPOs), retail partners, reimbursement experts, and an industry-leading third-party logistics provider. As part of an integrated national network with annual sales of over $1 billion in cancer therapeutics, DARA has significant commercial scale and capabilities. Its distribution network consists of more than 45,000 retail pharmacies, mail order pharmacies, and long-term care facilities. This provides DARA with established reimbursement and logistics expertise, as well as partnering opportunities with more than 300 sales and marketing personnel uniquely focused on oncology and oncology support products. This comprehensive network of partners is rare if not unique among companies in the oncology supportive care area and provides DARA a strong foundation for product introductions into this underserved market.